Androgenetic alopecia (AGA) is a genetically determined progressive hair-loss condition
which represents the most common cause of hair loss in men. The use of the medical term
androgenetic alopecia reflects current knowledge about the important role of androgens and genetic
factors in its etiology. In addition to androgen-dependent changes in the hair cycle, sustained
microscopic follicular inflammation contributes to its onset. Furthermore, Prostaglandins have been
demonstrated to have the ability in modulating hair follicle cycle; in particular, PGD2 inhibits hair
growth while PGE2/F2a promote growth. Due to the progressive nature of AGA, the treatment should
be started early and continued indefinitely, since the benefit will not be maintained upon ceasing
therapy. To date, only two therapeutic agents have been approved by the Food and Drug
Administration and European Medicines Agency for the treatment of AGA: topical minoxidil and oral
finasteride. Considering the many pathogenetic mechanisms involved in AGA, various treatment
options are available: topical and systemic drugs may be used and the choice depends on various
factors including grading of AGA, patients’ pathological conditions, practicability, costs and risks. So,
the treatment for AGA should be based on personalized therapy and targeted at the different
pathophysiological aspects of AG